Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Joann Harvey"'
1
Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1
Autor: Clifford A. Brass, Joann Harvey, Robert S. Brown, Firdous Siddiqui, Ira M. Jacobson, Michael S. Dragutsky, Louis Griffel, Greg Galler, Jonathan McCone, Paul Y. Kwo, Clive Albert, Thomas Hargrave, B. Freilich, Martin Black, Victor Araya, Louis R. Lambiase
Publikováno v: Hepatology. 46:982-990
WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PE
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d2b833c1cbb8a703698724af150b79d
https://doi.org/10.1002/hep.21670
Zobrazit plný text záznamu
2
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2
Autor: Janice K. Albrecht, Patrick Marcellin, Joann Harvey, José María Sánchez-Tapias, Clifford A. Brass, Tobias Goeser, Christoph Sarrazin, Rolf Hultcrantz, Stefan Zeuzem, Marc Bourlière
Publikováno v: Journal of Hepatology. 40:993-999
Background/Aims Treatment duration in patients with chronic hepatitis C in the era of standard interferon-α plus ribavirin was tailored according to hepatitis C virus (HCV) genotype: patients infected with HCV-1 were treated for 48 weeks, patients i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73f741a43c9aba230b6685a440aa8c8d
https://doi.org/10.1016/j.jhep.2004.02.007
Zobrazit plný text záznamu
3
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
Autor: John G. McHutchison, Mei-Hsiu Ling, Jean Jacques Garaud, Thierry Poynard, Jules L. Dienstag, Keyur Patel, Rafael Esteban-Mur, Zachary Goodman, Joann Harvey, Janice K. Albrecht, Gary L. Davis
Publikováno v: Hepatology. 35:688-693
The clinical use of measuring hepatic hepatitis C virus (HCV) RNA before and after therapy in patients with chronic hepatitis C has been assessed in a number of small clinical trials. Viral clearance from the liver may be a better marker of long-term
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11750340e77d0a0237265baa93a685f0
https://doi.org/10.1053/jhep.2002.31870
Zobrazit plný text záznamu
4
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
Autor: David L. Cutler, Frank Wagner, J.L. Poo, Connie Cullen, Ronald Bordens, Mark Laughlin, Joann Harvey, Marcelo Silva, Mary L. Jackson, Grace Michael
Publikováno v: Journal of hepatology. 45(2)
Background/Aims To compare the pharmacokinetics, pharmacodynamics, and antiviral activity of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C virus genotype 1. Methods Thirty-six patients were randomised to peginte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624c7e279fd3ecd1ee5b785049270263
https://pubmed.ncbi.nlm.nih.gov/17161495
Zobrazit plný text záznamu
5
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
Autor: Stefan, Zeuzem, Rolf, Hultcrantz, Marc, Bourliere, Tobias, Goeser, Patrick, Marcellin, Jose, Sanchez-Tapias, Christoph, Sarrazin, Joann, Harvey, Clifford, Brass, Janice, Albrecht
Publikováno v: Journal of hepatology. 40(6)
Treatment duration in patients with chronic hepatitis C in the era of standard interferon-alpha plus ribavirin was tailored according to hepatitis C virus (HCV) genotype: patients infected with HCV-1 were treated for 48 weeks, patients infected with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::94754291d65395a8b178cbd487384ded
https://pubmed.ncbi.nlm.nih.gov/15664255
Zobrazit plný text záznamu
6
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
Autor: John B. Wong, Michael P. Manns, Gary L. Davis, Janice K. Albrecht, Joann Harvey, John G. McHutchison
Publikováno v: Hepatology (Baltimore, Md.). 38(3)
Interferon-based regimens for the treatment of chronic hepatitis C have become increasingly effective and are able to eradicate virus in more than one half of cases. Early identification of patients who will not respond is desirable because treatment
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfc0ca198db4f23b2ba4d2f62b28daea
https://pubmed.ncbi.nlm.nih.gov/15131812
Zobrazit plný text záznamu
7
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
Autor: John G, McHutchison, Thierry, Poynard, Rafael, Esteban-Mur, Gary L, Davis, Zachary D, Goodman, Joann, Harvey, Mei-Hsiu, Ling, Jean Jacques, Garaud, Janice K, Albrecht, Keyur, Patel, Jules L, Dienstag, Timothy, Morgan
Publikováno v: Hepatology (Baltimore, Md.). 35(3)
The clinical use of measuring hepatic hepatitis C virus (HCV) RNA before and after therapy in patients with chronic hepatitis C has been assessed in a number of small clinical trials. Viral clearance from the liver may be a better marker of long-term
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5a71a9030b7b713499f080a89b7e6fc9
https://pubmed.ncbi.nlm.nih.gov/11870385
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje